The DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.
Peroxisome Proliferator-Activated Receptor γ Plays a Critical Role in Inhibition of Cardiac Hypertrophy In Vitro and In Vivo
Abstract
Background — Peroxisome proliferator-activated receptors (PPARs) are transcription factors of the nuclear receptor superfamily. It has been reported that the thiazolidinediones, which are antidiabetic agents and high-affinity ligands for PPARγ, regulate growth of vascular cells. In the present study, we examined the role of PPARγ in angiotensin II (Ang II)-induced hypertrophy of neonatal rat cardiac myocytes and in pressure overload-induced cardiac hypertrophy of mice. Methods and Results — Treatment of cultured cardiac myocytes with PPARγ ligands such as troglitazone, pioglitazone, and rosiglitazone inhibited Ang II-induced upregulation of skeletal α-actin and atrial natriuretic peptide genes and an increase in cell surface area. Treatment of mice with a PPARγ ligand, pioglitazone, inhibited pressure overload-induced increases in the heart weight-to-body weight ratio, wall thickness, and myocyte diameter in wild-type mice and an increase in the heart weight-to-body weight ratio in heterozygous PPARγ-deficient mice. In contrast, pressure overload-induced increases in the heart weight-to-body weight ratio and wall thickness were more prominent in heterozygous PPARγ-deficient mice than in wild-type mice. Conclusions — These results suggest that the PPARγ-dependent pathway is critically involved in the inhibition of cardiac hypertrophy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Levy, D., Garrison, R. J., Savage, D. D., Kannel, W. B., & Castelli, W. P. (1990) · New England Journal of Medicine · doi:10.1056/nejm199005313222203 · Cited by 5,699
The peroxisome proliferator-activated receptor-γ is a negative regulator of macrophage activation
Ricote, M., Li, A. C., Willson, T. M., Kelly, C. J., & Glass, C. K. (1998) · Nature · doi:10.1038/34178 · Cited by 3,525
PPAR-γ agonists inhibit production of monocyte inflammatory cytokines
Jiang, C., Ting, A. T., & Seed, B. (1998) · Nature · doi:10.1038/34184 · Cited by 2,899
A Calcineurin-Dependent Transcriptional Pathway for Cardiac Hypertrophy
Molkentin, J. D., Lu, J.-R., Antos, C. L., Markham, B., Richardson, J., Robbins, J., Grant, S. R., & Olson, E. N. (1998) · Cell · doi:10.1016/s0092-8674(00)81573-1 · Cited by 2,566
Sadoshima, J., & Izumo, S. (1993) · Circulation Research · doi:10.1161/01.res.73.3.413 · Cited by 1,427
PPARγ Mediates High-Fat Diet–Induced Adipocyte Hypertrophy and Insulin Resistance
Kubota, N., Terauchi, Y., Miki, H., Tamemoto, H., Yamauchi, T., Komeda, K., Satoh, S., Nakano, R., Ishii, C., Sugiyama, T., et al. (1999) · Molecular Cell · doi:10.1016/s1097-2765(00)80210-5 · Cited by 1,342
Self-citationKishimoto, T., Taga, T., & Akira, S. (1994) · Cell · doi:10.1016/0092-8674(94)90333-6 · Cited by 1,328
Schoonjans, K., Staels, B., & Auwerx, J. (1996) · Biochimica et Biophysica Acta (BBA) - Lipids and Lipid Metabolism · doi:10.1016/0005-2760(96)00066-5 · Cited by 1,047
Vidal-Puig, A. J., Considine, R. V., Jimenez-Liñan, M., Werman, A., Pories, W. J., Caro, J. F., & Flier, J. S. (1997) · Journal of Clinical Investigation · doi:10.1172/jci119424 · Cited by 786
Marx, N., Schönbeck, U., Lazar, M. A., Libby, P., & Plutzky, J. (1998) · Circulation Research · doi:10.1161/01.res.83.11.1097 · Cited by 587
Cited by
Cardiac Hypertrophy: The Good, the Bad, and the Ugly
Frey, N., & Olson, E. N. (2003) · Annual Review of Physiology · doi:10.1146/annurev.physiol.65.092101.142243 · Cited by 1,449
Cardiac fibroblasts: At the heart of myocardial remodeling
Porter, K. E., & Turner, N. A. (2009) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2009.05.002 · Cited by 1,010
Hypertrophy of the Heart: A New Therapeutic Target?
Frey, N., Katus, H. A., Olson, E. N., & Hill, J. A. (2004) · Circulation · doi:10.1161/01.cir.0000120390.68287.bb · Cited by 851
Huynh, K., Bernardo, B. C., McMullen, J. R., & Ritchie, R. H. (2014) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2014.01.003 · Cited by 553
Marx, N., Duez, H., Fruchart, J.-C., & Staels, B. (2004) · Circulation Research · doi:10.1161/01.res.0000127122.22685.0a · Cited by 501
Nuclear Receptor Signaling and Cardiac Energetics
Huss, J. M., & Kelly, D. P. (2004) · Circulation Research · doi:10.1161/01.res.0000141774.29937.e3 · Cited by 473
PGC-1α as a Pivotal Factor in Lipid and Metabolic Regulation
Cheng, C.-F., Ku, H.-C., & Lin, H. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19113447 · Cited by 437
Schirone, L., Forte, M., Palmerio, S., Yee, D., Nocella, C., Angelini, F., Pagano, F., Schiavon, S., Bordin, A., Carrizzo, A., et al. (2017) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2017/3920195 · Cited by 425
Peroxisome Proliferator-Activated Receptors: Vascular and Cardiac Effects in Hypertension
Schiffrin, E. L., Amiri, F., Benkirane, K., Iglarz, M., & Diep, Q. N. (2003) · Hypertension · doi:10.1161/01.hyp.0000084370.74777.b6 · Cited by 369
Cardiomyocyte expression of PPARγ leads to cardiac dysfunction in mice
Son, N.-H., Park, T.-S., Yamashita, H., Yokoyama, M., Huggins, L. A., Okajima, K., Homma, S., Szabolcs, M. J., Huang, L.-S., & Goldberg, I. J. (2007) · Journal of Clinical Investigation · doi:10.1172/jci30335 · Cited by 335
Cardiac fibrosis: new insights into the pathogenesis
Ma, Z.-G., Yuan, Y.-P., Wu, H.-M., Zhang, X., & Tang, Q.-Z. (2018) · International Journal of Biological Sciences · doi:10.7150/ijbs.28103 · Cited by 331
Safety issues and prospects for future generations of PPAR modulators
RUBENSTRUNK, A., HANF, R., HUM, D., FRUCHART, J., & STAELS, B. (2007) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/j.bbalip.2007.02.003 · Cited by 309
Palomer, X., Salvadó, L., Barroso, E., & Vázquez-Carrera, M. (2013) · International Journal of Cardiology · doi:10.1016/j.ijcard.2013.07.150 · Cited by 289
Thiazolidinediones in Type 2 Diabetes Mellitus: Current Clinical Evidence
Diamant, M., & Heine, R. J. (2003) · Drugs · doi:10.2165/00003495-200363130-00004 · Cited by 277
Mitochondria in cardiac hypertrophy and heart failure
Rosca, M. G., Tandler, B., & Hoppel, C. L. (2013) · Journal of Molecular and Cellular Cardiology · doi:10.1016/j.yjmcc.2012.09.002 · Cited by 267
Genetic causes of human heart failure
Morita, H., Seidman, J. G., & Seidman, C. E. (2005) · Journal of Clinical Investigation · doi:10.1172/jci200524351 · Cited by 264
The Toxicology of Ligands for Peroxisome Proliferator-Activated Receptors (PPAR)
Peraza, M. A., Burdick, A. D., Marin, H. E., Gonzalez, F. J., & Peters, J. M. (2006) · Toxicological Sciences · doi:10.1093/toxsci/kfj062 · Cited by 254
LIAO, Y., TAKASHIMA, S., MAEDA, N., OUCHI, N., KOMAMURA, K., SHIMOMURA, I., HORI, M., MATSUZAWA, Y., FUNAHASHI, T., & KITAKAZE, M. (2005) · Cardiovascular Research · doi:10.1016/j.cardiores.2005.04.018 · Cited by 236
Angiotensin-Converting enzyme inhibition and angiogenesis in myocardium of obese Zucker rats
Toblli, J. (2004) · American Journal of Hypertension · doi:10.1016/j.amjhyper.2003.10.006 · Cited by 71
Biology and Therapeutic Applications of Peroxisome Proliferator- Activated Receptors
P. Menendez-Gutierrez, M., Roszer, T., & Ricote, M. (2012) · Current Topics in Medicinal Chemistry · doi:10.2174/156802612799436669 · Cited by 62
McGuire, D. K., Abdullah, S. M., See, R., Snell, P. G., McGavock, J., Szczepaniak, L. S., Ayers, C. R., Drazner, M. H., Khera, A., & de Lemos, J. A. (2010) · European Heart Journal · doi:10.1093/eurheartj/ehq228 · Cited by 29
Metadata
- Authors
- Asakawa, M., Takano, H., Nagai, T., Uozumi, H., Hasegawa, H., Kubota, N., Saito, T., Masuda, Y., Kadowaki, T., & Komuro, I.
- Venue
- Circulation
- Published
- 2002-03-12
- Volume
- 105
- Issue
- 10
- Pages
- 1240-1246
- ISSN
- 0009-7322 (ISSN-L)
- 1524-4539
- OpenAlex
- W2167767922
- Cited by
- 255
- References
- 30
- FWCI
- 7.02
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.